The U.S. Food and Drug Administration (FDA) has approved ABECMA® (idecabtagene vicleucel; ide-cel), from Bristol Myers Squibb and bluebird bio, Inc. ABECMA is the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) after four or more prior ... Continue Reading